Results 121 to 130 of about 16,563 (220)

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic cancer: A prospective study

Nutrition in Clinical Practice, Volume 41, Issue 4, Page 1157-1165, August 2026.
Abstract Background Pancreatic enzyme insufficiency (PEI) contributes to symptom burden and malnutrition in advanced pancreatic cancer (aPC). We aimed to evaluate the impact of pancreatic enzyme replacement therapy (PERT) on symptom burden and weight during chemotherapy.
Pamela N. Klassen, Christina A. Kim, Jessica Kasnik, Michael B. Sawyer, Sunita Ghosh, Vickie Baracos, Vera C. Mazurak   +6 more
wiley   +1 more source

Deciphering the Functional Mechanisms of eIF3f in Tumors and Exploring Targeted Therapies

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Eukaryotic translation initiation factor 3 subunit F (eIF3f) is a critical component of the eIF3 complex and plays a pivotal role in diverse biological processes, including cell proliferation, apoptosis, adhesion, and transcriptional regulation.
Yujinpeng Hao, Jun Shao, Naqi Lian, Mianli Bian   +3 more
wiley   +1 more source

Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study. [PDF]

Ther Adv Med Oncol
Tseng KY, Hsu CY, Wu CH, Shih YH, Lin HC.   +4 more
europepmc   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

The Efficacy and Safety of Nab-Paclitaxel Plus Anlotinib in Small-Cell Lung Cancer for Second-Line Therapy. [PDF]

Thorac Cancer
Tian LJ, Zhou FF, Dai M, Liu JL, Guo QS.
europepmc   +1 more source

Pembrolizumab combined with nab-paclitaxel and platinum in recurrent/metastatic HNSCC: efficacy, safety, and survival predictive model. [PDF]

ESMO Open
Tang L, Gao R, Yao J, Zhang W, Zhang Y, Zhang Y, Lu H, An C, Gui L.   +8 more
europepmc   +1 more source

Is FOLFIRINOX more effective than gemcitabine plus nab-paclitaxel in pancreatic adenocarcinoma? -a decade of debate! [PDF]

J Gastrointest Oncol
Babiker HM.
europepmc   +1 more source

Cost-effectiveness analysis of nab-paclitaxel with or without relacorilant for platinum-resistant ovarian cancer. [PDF]

J Ovarian Res
Lai S, Lai S, Xu X, Huang W, Chen Q, He S, Xue H.   +6 more
europepmc   +1 more source

Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France). [PDF]

EClinicalMedicine
Taieb J, Pernot S, Thuillier F, Delattre A, Vo-Quang E, Petorin C, Bourgeois V, Tougeron D, Audemar F, Vitellius C, Mosser L, Desrame J, Di Fiore F, Rinaldi Y, Pellat A, Bolliet M, Watelle F, Perrier H, Dubreuil O, Lepage C, Bachet JB.   +20 more
europepmc   +1 more source